Such a difference in the efficiency of hydrolysis of miR-219-2-3p by IgGs from the blood of various MS patients may be due to the fact that in some of them, the formation of Abs and abzymes that are specifically against miR-219-2-3p is ineffective or almost does not occur. The gene discussed is DDX41; the disease is myeloid sarcoma.